The proportion of primary MET gene amplification in NSCLC is 1%–5% (18), which is often secondary to targeted therapy in other driver gene-positive patients with NSCLC and is recognized as one of the important mechanisms related to EGFR-TKI resistance. The gene discussed is MET; the disease is non-small cell lung carcinoma.